Kennesaw, GA—The prebiotic PreforPro, a proprietary blend of bacteriophages, has been shown in a clinical trial to promote the balance of good bacteria in the microbiome, according to a press release from Deerland Probiotics and Enzymes.
The study, published in Nutrients, was a randomized, double-blind, placebo-controlled, parallel-arm clinical intervention trial. 66 participants were assigned to one of three groups: placebo; 1 billion CFU Bifidobacterium animalis BL04 (B. lactis BL04); or 1 billion CFU B. lactis BL04 plus 15mg PreforPro. Participants took one capsule per day for four weeks.
The B. lactis BL04 plus PreforPro group showed the following:
- Improvements in self-reported GI inflammation symptoms
- Reduction in colonic cramp discomfort
- Greater increase in the presence of Lactobacillus vs. placebo
- Decrease of strains Citrobacter and Desulfovibrio, which are associated with gut inflammation and GI disorders
- Reduction in E. coli
Related: Deerland Integration of Bifodan A/S Now Complete
Study: Enzyme Blend ProHydrolase Enhances Benefit of Whey Protein
The press release sums up: “The study demonstrates that supplementing B. lactis BL04 with PreforPro can significantly modulate gut ecology to favor beneficial bacteria.”
John Deaton, VP of Science and Technology at Deerland, expanded on that: “In addition, a lack of global changes to the microbiota (dysbiosis) in combination with specific modulation of certain taxa, like Lactobacillus, suggests that PreforPro displays prebiotic-like effects and may extend the GI benefits of consuming B. lactis or other probiotics. This study demonstrates the opportunity and capability of phages in the robust support of healthy microflora balance and the associated physiological benefits. Phages are clearly up-and-coming supplements in the rapidly burgeoning arena of microbiome support.”